# A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma

> **NCT05528679** · PHASE2 · UNKNOWN · sponsor: **Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** 610 100mg
- **DRUG:** 610 300mg
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05528679
- **Lead sponsor:** Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09
- **Primary completion:** 2023-09
- **Final completion:** 2023-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05528679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05528679, "A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05528679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*